Immunogenicity and Safety Study of GSK Biologicals' Quadrivalent Influenza Vaccine (GSK2282512A) When Administered in Children.

Trial Profile

Immunogenicity and Safety Study of GSK Biologicals' Quadrivalent Influenza Vaccine (GSK2282512A) When Administered in Children.

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Feb 2016

At a glance

  • Drugs GSK 2282512A (Primary) ; Influenza virus vaccine
  • Indications Influenza A virus infections; Influenza B virus infections
  • Focus Pharmacodynamics; Registrational
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 22 Nov 2012 Primary endpoint 'Humoral-immune-response' in children aged 3-17 years has been met, according to a GlaxoSmithKline media release.
    • 30 Jul 2012 Actual end date (1 Jul 2011) added as reported by ClinicalTrials.gov.
    • 01 Jul 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top